Researchers Karijn Suijkerbuijk

Karijn Suijkerbuijk

Full Professor

Strategic program(s):

Biography

Karijn Suijkerbuijk is a translational medical oncologist with special interest in melanoma and immunotherapy. During her PhD, she performed research on tumor epigenetics in breast cancer in the lab of Professor Saraswati Sukumar at the Sidney Kimmel Cancer Center at Johns Hopkins University. Dr. Suijkerbuijk currently participates in multiple phase II and III clinical trials on immune checkpoint inhibitors. She published papers in Oncogene, Annals of Oncology and JNCI, received research grants from KWF and NWO and was awarded an ASCO Merit Award. Her current research focuses on clinical and immunological parameters assoaciated with immune related adverse events during checkpoint inhibition and clinicopathological factors associated with checkpoint inhibitor response.

Strategic program(s):

Contact

ksuijke2@umcutrecht.nl

Pure profile

Research groups

Molecular and cellular host-microbiota interactions

Research aim

Our research aims to unravel how the products from pathogenic and beneficial bacterial species within the intestinal microbiota contribute to human health and disease.

Go to group

Immunotherapy in solid tumors

Research aim

Our research aims at accomplishing cure and good quality of life for more and more patients with metastatic cancer by: - AI-based early identification of (non-)responders to current immunotherapy - new immunotherapies for non-responders - developing strategies to treat immunotherapy toxicity without compromising efficacy

Go to group

Recent publications

All publications

ESMO Adaptation of Lines of Systemic Therapy (EnLiST) K S Saini, M Koopman, D Martins-Branco, P Bossi, S Braendegaard Winther, M Brahmi, I Braña, E Calvo, L Castelo-Branco, I Colombo, E de Azambuja, D De Ruysscher, R Dienstmann, A-M C Dingemans, M Ekholm, C Gallois, V Golfinopoulos, E Grande, S Halabi, E Le Rhun, O Le Saux, N B Leighl, S Lonardi, S Lorenzen, D Lorusso, Giuseppe Minniti, G Mountzios, J Oldenburg, S F Oosting, P Osterlund, J L Perez-Gracia, A Pellat, S Piperno-Neumann, R Plummer, C Porta, K Punie, I Ray-Coquard, J Remon, C H Ruhlmann, P Rutkowski, L L Siu, S Stacchiotti, C Suarez, K Suijkerbuijk, J Taieb, D Trapani, A Valachis, H W M van Laarhoven, A Vogel, A Zer, G Pentheroudakis, S Delaloge, C Twelves
Annals of oncology : official journal of the European Society for Medical Oncology, 2026, vol. 37, p.608-623

Neoadjuvant ipilimumab plus nivolumab in melanoma Lotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen, Irene L M Reijers, Marta Lopez-Yurda, Alexander M Menzies, Annegien Broeks, Sten Cornelissen, Alejandro Torres Acosta, Anja van der Wal, Robyn P M Saw, Judith M Versluis, Winan J van Houdt, Michel W Wouters, Jurriaan Romano, Eliza A Rozeman, Lindsay G Grijpink-Ongering, Ellen Kapiteijn, Astrid A M van der Veldt, Karijn P M Suijkerbuijk, Hanna Eriksson, Geke A P Hospers, Jos A van der Hage, Dirk J Grünhagen, Arjen J Witkamp, Judith M Lijnsvelt, Willem M C Klop, Charlotte L Zuur, Annemarie Bruining, Abrahim Al-Mamgani, Thomas E Pennington, Kerwin F Shannon, Sydney Ch'ng, Andrew J Colebatch, Maria Gonzalez, Andrew J Spillane, John B A G Haanen, Robert V Rawson, Richard A Scolyer, Bart A van de Wiel, Alexander C J van Akkooi, Georgina V Long, Christian U Blank
Nature medicine, 2026, vol. 32, p.952-963

Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer E J van Dijk, M M Smeenk, F Bensch, A M Sadowksa, M V Verschueren, M Verhaert, A Llobell, Y Suzuki, D F L Liew, A Takeji, A T J Maria, B J M Peters, J S Garcia Morillo, K Chatzidionysiou, M Lidar, E C van der Hout, S Aspeslagh, G J M Herder, E M W van de Garde, L E L Hendriks, L B M Hijmering-Kappelle, W S M E Theelen, K P M Suijkerbuijk, R J Verheijden
ESMO open, 2026, vol. 11

ESMO Basic Requirements for AI-based Biomarkers In Oncology (EBAI) M Aldea, M Salto-Tellez, A Marra, R Umeton, A Stenzinger, M Koopman, A Prelaj, K L Kehl, S Gilbert, M-E Leßmann, J Lipkova, L Provenzano, F Meric-Bernstam, S Halabi, J Wu, A Pellat, K P M Suijkerbuijk, B Besse, B Ryll, C Marchió, M Crispin-Ortuzar, R Fehrmann, J Vibert, D Ferber, C Pauli, A Valachis, Federica Corso, T J Brinker, J Mateo, N Harbeck, E C Winkler, F Lopez-Rios, R Perez-Lopez, G Pentheroudakis, S Delaloge, C Benedikt Westphalen, J N Kather
Annals of oncology : official journal of the European Society for Medical Oncology, 2025, vol. 37, p.414-430

Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events Mick J M van Eijs, M Marlot van der Wal, Hedi-Britt Klotškova, Noël M M Dautzenberg, Mark Schuiveling, Rik J Verheijden, Fiona D M van Schaik, Bas Oldenburg, Stefan Nierkens, Karijn P M Suijkerbuijk, Femke van Wijk,
Communications medicine, 2025, vol. 5, p.1-14

Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma M Bloem, A J M van den Eertwegh, J B A G Haanen, M J B Aarts, F W P J van den Berkmortel, C U Blank, W A M Blokx, M J Boers-Sonderen, C D M Boreel, J W B de Groot, G A P Hospers, E Kapiteijn, D Piersma, B Rikhof, L H J Simkens, A M Stevense-den Boer, A A M van der Veldt, M W J M Wouters, K P M Suijkerbuijk
European Journal of Cancer, 2025, vol. 230

Fellowships & Awards

2007  Research year for residents (UU2007-3977) KWF
2008  Translational grant KWF (UU-2008-4217
2008  AGIKO stipend, ZonMW
2008  ASCO Merit Award

2018 ZonMW goed gebruik geneesmiddelen

External positions

lead author melanoom richtlijn - coordineren Europese melanoom richtlijn - ESMO

research funding Genmab - AI onderzoekssamenwerking in Health Holland project dat door Genmab financieel wordt ondersteund - Genmab

ESMO melanoma faculty - expertise melanoom - European Society for Medical Oncology

Lid real world data working group ESMO - onderzoek patientcohorten - European Society for Medical Oncology

Lid wetenschappelijke adviesraad - ervaring onderzoek - Maarten van der Weijden foundation

Adviesraad stichting melanoom (sinds 2019) - Vanuit expertise als melanoombehandelaar - Stichting melanoom

Lid Data Safety Monitoring Committee CHOPIN studie (vanaf 2020; studie gesponsord door BMS) - onderzoekservaring immuuntherapie - LUMC

Voorzitter wetenschappelijke commissie - Kwaliteitsverbetering en onderzoek op het gebied van melanoomzorg - Dutch Melanoma Treatment Registry (DICA)

Adviesgroep kanker in de zwangerschap - Expertise melanoom en immuuntherapie - Adviesgroep kanker in de zwangerschap

Organisatie/voorzitter jaarlijks immuno-oncologie symposium - expertise en onderzoek immuunoncologie - Immuno-oncologie symposium

Bestuurslid Tumorfocusgroep melanoom - expertise melanoom - Tumorfocusgroep melanoom

medisch expert bij melanoom nascholing en congresjournaal ASCO/ESMO - expertise melanoom - Medtalks